Cambrex Corporation (CBM) Holdings Trimmed by Navellier & Associates Inc

Navellier & Associates Inc trimmed its stake in shares of Cambrex Corporation (NYSE:CBM) by 14.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,877 shares of the biotechnology company’s stock after selling 2,017 shares during the period. Navellier & Associates Inc’s holdings in Cambrex Corporation were worth $710,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in CBM. BlackRock Inc. lifted its holdings in shares of Cambrex Corporation by 156,940.2% during the first quarter. BlackRock Inc. now owns 4,002,955 shares of the biotechnology company’s stock valued at $220,363,000 after purchasing an additional 4,000,406 shares during the last quarter. FMR LLC lifted its holdings in shares of Cambrex Corporation by 78.2% during the first quarter. FMR LLC now owns 899,086 shares of the biotechnology company’s stock valued at $49,494,000 after purchasing an additional 394,638 shares during the last quarter. Marshall Wace North America L.P. lifted its holdings in shares of Cambrex Corporation by 2,239.4% during the second quarter. Marshall Wace North America L.P. now owns 266,106 shares of the biotechnology company’s stock valued at $15,966,000 after purchasing an additional 254,731 shares during the last quarter. Clearbridge Investments LLC lifted its holdings in shares of Cambrex Corporation by 34.8% during the first quarter. Clearbridge Investments LLC now owns 971,174 shares of the biotechnology company’s stock valued at $53,463,000 after purchasing an additional 250,662 shares during the last quarter. Finally, OppenheimerFunds Inc. lifted its holdings in shares of Cambrex Corporation by 4,081.5% during the first quarter. OppenheimerFunds Inc. now owns 224,798 shares of the biotechnology company’s stock valued at $12,375,000 after purchasing an additional 219,422 shares during the last quarter.

Several equities research analysts have recently commented on the company. Zacks Investment Research downgraded Cambrex Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, July 4th. BidaskClub raised Cambrex Corporation from a “hold” rating to a “buy” rating in a report on Friday, August 4th. Finally, ValuEngine downgraded Cambrex Corporation from a “buy” rating to a “hold” rating in a report on Friday, September 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $65.67.

TRADEMARK VIOLATION WARNING: This report was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.dispatchtribunal.com/2017/10/27/navellier-associates-inc-has-710000-position-in-cambrex-corporation-cbm.html.

In related news, CEO Steven M. Klosk sold 4,000 shares of the company’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $54.96, for a total transaction of $219,840.00. Following the sale, the chief executive officer now owns 87,328 shares in the company, valued at $4,799,546.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Steven M. Klosk sold 12,000 shares of the company’s stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $61.39, for a total value of $736,680.00. Following the sale, the chief executive officer now owns 95,328 shares in the company, valued at approximately $5,852,185.92. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 28,000 shares of company stock worth $1,574,880. Corporate insiders own 2.48% of the company’s stock.

Shares of Cambrex Corporation (NYSE:CBM) traded down 7.720% during midday trading on Friday, reaching $45.125. The company had a trading volume of 264,675 shares. Cambrex Corporation has a 52-week low of $38.30 and a 52-week high of $62.95. The firm has a market cap of $1.48 billion, a P/E ratio of 16.439 and a beta of 2.28. The company’s 50-day moving average is $53.21 and its 200-day moving average is $55.33.

Cambrex Corporation (NYSE:CBM) last posted its earnings results on Friday, August 4th. The biotechnology company reported $0.76 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.76. The firm had revenue of $134.55 million for the quarter, compared to analyst estimates of $136.82 million. Cambrex Corporation had a return on equity of 24.25% and a net margin of 17.70%. The company’s revenue for the quarter was up 13.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.68 earnings per share. Equities research analysts expect that Cambrex Corporation will post $3.08 EPS for the current fiscal year.

Cambrex Corporation Company Profile

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Institutional Ownership by Quarter for Cambrex Corporation (NYSE:CBM)

Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply